ANIK vs. RGNX: Which Stock Should Value Investors Buy Now?

Shutterstock photo

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Anika Therapeutics (ANIK) and Regenxbio (RGNX). But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.

Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.

Anika Therapeutics has a Zacks Rank of #1 (Strong Buy), while Regenxbio has a Zacks Rank of #3 (Hold) right now. This means that ANIK's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. But this is only part of the picture for value investors.

Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.

Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use.

ANIK currently has a forward P/E ratio of 35.20, while RGNX has a forward P/E of 37.15. We also note that ANIK has a PEG ratio of 3.52. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. RGNX currently has a PEG ratio of 12.22.

Another notable valuation metric for ANIK is its P/B ratio of 2.03. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, RGNX has a P/B of 6.13.

These metrics, and several others, help ANIK earn a Value grade of B, while RGNX has been given a Value grade of F.

ANIK stands above RGNX thanks to its solid earnings outlook, and based on these valuation figures, we also feel that ANIK is the superior value option right now.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Anika Therapeutics Inc. (ANIK): Free Stock Analysis Report

REGENXBIO Inc. (RGNX): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing , Investing Ideas , Stocks
Referenced Symbols: ANIK , RGNX

More from Zacks.com




Equity Research

Research Brokers before you trade

Want to trade FX?